Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Pembrolizumab Improves Survival in PD-L1+ Esophageal Cancer

November 15th 2018

Second-line treatment with pembrolizumab improved overall survival versus chemotherapy in patients with advanced or metastatic esophageal or esophagogastric junction carcinoma whose tumors expressed PD-L1.

Dr. O'Connor on Real-World Results With Regorafenib in mCRC

November 13th 2018

Juan Manuel O’Connor, MD, head, Department Gastrointestinal Oncology, Department of Clinical Oncology, Institute Alexander Fleming, Buenos Aires, discusses real-world results with regorafenib (Stivarga) in the treatment of patients with metastatic colorectal cancer (mCRC).

Dr. Mody Discusses Treatment Options for HCC

November 13th 2018

Kabir Mody, MD, medical oncologist, Mayo Clinic, discusses treatment options for patients with hepatocellular carcinoma.

FDA Approves Pembrolizumab for HCC

November 10th 2018

The FDA has approved pembrolizumab for the treatment of patients with hepatocellular carcinoma who have previously received sorafenib.

Dr. Strosberg Discusses Updates From the NETTER-1 Study

November 9th 2018

Jonathan Strosberg, MD, associate professor, Moffitt Cancer Center, discusses updates from the NETTER-1 study in patients with neuroendocrine tumors (NETs).

Dr. Bekaii-Saab on the Impact of Next-Generation Sequencing in mCRC

November 9th 2018

Tanios Bekaii-Saab, MD, medical oncologist, Mayo Clinic, discusses the utility of next-generation sequencing in metastatic colorectal cancer (mCRC).

Prodrugs in Oncology: Teaching Old and New Drugs More Tricks

November 7th 2018

As researchers gain a better understanding of the unique aspects of individual tumor types and their surrounding microenvironment, the design of novel therapies categorized as prodrugs is become increasingly sophisticated, and several novel constructs show particular promise.

Dr. Iqbal on the Biggest Advance in the Treatment of Neuroendocrine Tumors

November 6th 2018

Syma Iqbal, MD, associate professor of clinical medicine, Keck School of Medicine, University of Southern California, discusses the impact of peptide receptor radionuclide therapy (PRRT) on the treatment of patients with neuroendocrine tumors (NETs).

Dr. Barzi on Available and Emerging Neoadjuvant Approaches in Pancreatic Cancer

November 6th 2018

Afsaneh Barzi, MD, assistant professor of clinical medicine, Norris Comprehensive Cancer Center, University of Southern California, discusses available and emerging neoadjuvant strategies for the treatment of patients with nonmetastatic pancreatic cancer.

Obesity Impact Draws Increased Scrutiny in GI Malignancies

November 6th 2018

Obesity is associated with an increased risk of early-onset colorectal cancer among women and correlates with higher rates of cancer resections in gastrointestinal malignancies across age groups.

ASCO Urges Routine dMMR Testing for Second-Line Metastatic Pancreatic Cancer

November 5th 2018

Based on fresh studies in the setting of metastatic pancreatic cancer, the American Society of Clinical Oncology now recommends routine testing for mismatch repair deficiency or high microsatellite instability for candidates for checkpoint inhibitor therapy.

Dr. Pishvaian Discusses Atezolizumab Plus Bevacizumab in HCC

November 2nd 2018

Michael Pishvaian, MD, PhD, director, Phase I Clinical Program, co-director of the Ruesch Center Pancreatic Cancer Program Medical Oncology, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, Georgetown University Lombardi Comprehensive Cancer Center, discusses the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) in patients with hepatocellular carcinoma.

Dr. McCollum on the Clinical Utility of Regorafenib in mCRC

November 2nd 2018

A. David McCollum, MD, attending oncologist, Baylor University Medical Center, discusses the clinical utility of regorafenib (Stivarga) in metastatic colorectal cancer (mCRC).

Infigratinib Findings in IHC Highlight Importance of Molecular Testing

November 1st 2018

Milind Javle, MD, discusses findings from a phase II study of infigratinib in patients with intrahepatic cholangiocarcinoma, emphasizing the importance of molecular testing.

Treatment Updates Move Neuroendocrine Tumor Paradigm Forward

October 31st 2018

Syma Iqbal, MD, discusses the evolving treatment paradigm of neuroendocrine tumors.

Role of Immunotherapy May Expand in Gastric/GEJ Cancers

October 31st 2018

The second-line treatment of gastric and gastroesophageal junction cancers has shifted considerably in the last few years, due in part to the addition of immunotherapy for select subgroups of patients.

Dr. Cercek on Induction Chemotherapy in Mismatch Repair Deficient Rectal Cancer

October 29th 2018

Andrea Cercek, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses induction chemotherapy in patients with mismatch repair deficient rectal cancer.

Real-World Results Reveal Regorafenib Tolerability in mCRC

October 29th 2018

Juan Manuel O’Connor, MD, discusses the final results of the CORRELATE regorafenib study in patients with metastatic colorectal cancer, emphasizing the importance of real-world data.

Dr. Lenz on the Benefit of Regorafenib in CRC

October 26th 2018

Heinz-Josef Lenz, MD, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses the benefit of regorafenib (Stivarga) in the treatment of patients with colorectal cancer (CRC).

FDA Grants Priority Review to TAS-102 for Gastric/GEJ Cancer

October 26th 2018

The FDA has granted a priority review to a supplemental new drug application for TAS-102 for use in previously treated patients with advanced or metastatic gastric adenocarcinoma, including cancer of the gastroesophageal junction.